Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Integromics announces winners of proteomics grant competition

Integromics, a leader in IT solutions for life sciences in the field of genomics and proteomics, today announces the two winners of the Integromics 'Proteomics Mass Spectrometry Research Grant' competition, for the creative use of Integromics' OmicsHub(R) proteomics solution. The winners are Prof. Stephen Pennington from University College Dublin and Dr. Michelle Cilia from the USDA-ARS (U.S. Department of Agriculture - Agricultural Research Service).

22 Jun 2011

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification.

21 Jun 2011

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Researchers from Boston University School of Medicine (BUSM) have found that among HIV-infected adults with alcohol problems, measuring their carbohydrate-deficient transferrin (CDT) biomarker was a poor and inaccurate method for detecting unhealthy drinking.

21 Jun 2011

Genetic biomarker may help identify patients at increased risk of bypass surgery

Outcomes of bypass surgery to repair blocked arteries in the legs tend to be better in the roughly one-in-five people who have inherited a specific genetic variation from both parents, according to a study presented at the late-breaking clinical trials session of the Vascular Annual Meeting in Chicago on June 18, 2011.

20 Jun 2011

Randox launches automated laboratory assay for Heart-type Fatty Acid Binding Protein

Randox Laboratories, the international clinical diagnostics company, has today launched an automated laboratory assay for Heart-type Fatty Acid Binding Protein (H-FABP), to improve the diagnosis and management of patients with suspected acute coronary syndrome (ACS).

From Randox Laboratories Ltd. 20 Jun 2011

Novel biomarker-development pipeline approach for human diseases

Researchers at Fred Hutchinson Cancer Research Center have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans.

20 Jun 2011

Key to remove stem cells responsible for fat expansion

Researchers may have found the key to developing a method to rid the body of stem cells responsible for driving fat expansion. According to a report in the June 16 Cell Stem Cell, a Cell Press publication, they've landed the first protein marker on the surface of those so-called adipose stromal cells (ASCs), which serve as progenitors of the cells that make up fat tissue.

17 Jun 2011

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

Predictive Biosciences, a provider of novel molecular diagnostic tests, announced that on June 7, 2011 the U.S. Patent and Trademark Office issued Patent Number 7,955,822 for "Detection of Nucleic Acids and Proteins".

17 Jun 2011

ADDF, AFTD invite scientists to apply for Frontotemporal Dementia-specific biomarker grants

The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be monitored.

16 Jun 2011

DiagnoCure receives new U.S. patent for PCA3 prostate cancer biomarker portfolio

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported the issuance of a new U.S. patent, which represents a significant addition to DiagnoCure's PCA3 prostate cancer biomarker portfolio.

16 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

immatics initiates IMA901 Phase III trial in renal cell carcinoma

igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma.

15 Jun 2011

Actelion awards grants to 2011 ENTELLIGENCE young investigators for research in pulmonary arterial hypertension

Actelion Pharmaceuticals US, Inc. and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors for their efforts in advancing research in PAH. Each researcher will receive a 12-month mentored grant of up to $100,000 in support, funded through the ENTELLIGENCE program supported by Actelion. The announcement was made at an awards luncheon, during which the recipients of the 2011 awards gave an overview of their proposed work.

14 Jun 2011

FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test

Mitsubishi Chemical Medience Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) premarketing notification clearance to the PATHFAST cTnI-II diagnostic test, clearing the way for its sale in the United States.

14 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

ST2 biomarker can help indicate prognosis in ambulatory cardiovascular patients

The novel cardiac biomarker ST2 was highlighted in a presentation at last month's 2011 Heart Failure Congress of the European Society of Cardiology in Gothenburg, Sweden. As this study and others have demonstrated, a patient's ST2 level can help a physician better predict prognosis in ambulatory, chronic heart failure patients, which can allow physicians to more appropriately tailor care.

10 Jun 2011

LGL to host third annual pharmacogenetic conference on 8-9th November 2011

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that its third annual pharmacogenetic conference will feature top-level presentations from players in all parts of the healthcare chain.

10 Jun 2011

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomics Analysis Reveals Elevation of 3-Indoxyl Sulfate in Plasma and Brain during Chemically-induced Acute Kidney Injury in Mice: Investigation of Nicotinic Acid Receptor Agonists", in Toxicology and Applied Pharmacology.

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Biomarker News and Research

Further Reading

Integromics announces winners of proteomics grant competition

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Genetic biomarker may help identify patients at increased risk of bypass surgery

Randox launches automated laboratory assay for Heart-type Fatty Acid Binding Protein

Novel biomarker-development pipeline approach for human diseases

Key to remove stem cells responsible for fat expansion

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

ADDF, AFTD invite scientists to apply for Frontotemporal Dementia-specific biomarker grants

DiagnoCure receives new U.S. patent for PCA3 prostate cancer biomarker portfolio

QIAGEN to acquire Ipsogen

immatics initiates IMA901 Phase III trial in renal cell carcinoma

Actelion awards grants to 2011 ENTELLIGENCE young investigators for research in pulmonary arterial hypertension

FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

Larger trial study needed to decide fate of niacin

ST2 biomarker can help indicate prognosis in ambulatory cardiovascular patients

LGL to host third annual pharmacogenetic conference on 8-9th November 2011

Metabolomics analysis shows 3IS as early predictive, sensitive biomarker of acute kidney injury

Patient enrollment complete in cilengitide Phase III study against glioblastoma

eBook: Cellular Senescence eBook

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest Life Science News